<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478244</url>
  </required_header>
  <id_info>
    <org_study_id>MT2006-15</org_study_id>
    <secondary_id>CDR0000546620</secondary_id>
    <secondary_id>UMN-0702M01504</secondary_id>
    <nct_id>NCT00478244</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa</brief_title>
  <official_title>Allogeneic Hematopoietic Cell Transplantation to Correct the Biochemical Defect and Create Tolerance to Donor Tissue in Subjects With Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: In animal models, stem cells have been shown to home to the skin and repair the
      biochemical and structural abnormalities associated with recessive dystrophic epidermolysis
      bullosa (RDEB) (collagen 7 deficiency).

      PURPOSE: To determine the safety and effectiveness of stem cell infusion in the treatment of
      RDEB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Estimate the incidence of detectable donor-derived collagen type VII at day 100 in
           patients with epidermolysis bullosa by donor.

      Secondary

        -  Determine the incidence of transplant-related mortality at day 180

        -  Determine the incidence of blood chimerism at days 21, 100, 180, 365, and 730

        -  Determine the incidence of neutrophil recovery at day 42 and platelet recovery at day
           180

        -  Determine the incidence of acute graft-versus-host disease (GVHD) grade II-IV and grade
           III-IV at day 100

        -  Determine the incidence of chronic GVHD at 1 year

        -  Determine the probability of survival at 1 and 2 years

        -  Determine the incidence of donor derived cells in the skin

        -  Determine resistance to blister formation OUTLINE: This is an open-label, pilot study.

        -  Conditioning regimen: Busulfan intravenously (IV) over 2 hours every 6 hours on days -9
           to -4, fludarabine phosphate IV over 1 hour on days -5 to -3, and high-dose
           cyclophosphamide IV over 1 hour on days -5 to -2.

        -  Stem cell transplantation on day 0.

      After completion of study treatment, patients are followed periodically for at least 5 years.

      PROJECTED ACCRUAL: 30 patients
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Competing studies
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Detectable Collagen Type VII</measure>
    <time_frame>Day 100 Post Transplant</time_frame>
    <description>Number of patients with epidermolysis bullosa who had collagen type VII. Type VII collagen defects cause recessive dystrophic epidermolysis bullosa (RDEB), a blistering skin disorder often accompanied by epidermal cancers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With &gt;70% Donor Chimerism</measure>
    <time_frame>Days 21, 100, 180, 365 and 730 Post Transplant</time_frame>
    <description>Number of patients with donor chimerism - percentage of donor cells in the patient via the peripheral blood or bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Transplant-Related Mortality</measure>
    <time_frame>Day 180 Post Transplant</time_frame>
    <description>Number of patients who died due to complications of the transplant (includes all deaths without previous relapse or progression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Platelet Engraftment</measure>
    <time_frame>Day 180 Post Transplant</time_frame>
    <description>Number of patients with a platelet count &gt;5 x 10^10 cells/liter for 3 consecutive measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Acute Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>Day 100 Post Transplant</time_frame>
    <description>Number of patients with GVHD. Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Chronic Graft-Versus-Host Disease (cGVHD)</measure>
    <time_frame>Day 365 Post Transplant</time_frame>
    <description>Number of patients with cGVHD; a severe long-term complication created by infusion of donor cells into a foreign host.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year and 2 years Post Transplant</time_frame>
    <description>Survival is defined as the number of patients that were alive post transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Donor Derived Cells in Skin</measure>
    <time_frame>Day 90 Post Transplant</time_frame>
    <description>Number of patients who had donor skin chimerism - donor cells in the patient's epidermis (a state in bone marrow transplantation in which bone marrow and host cells exist compatibly without signs of graft-versus-host rejection disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Resistance to Blister Formation</measure>
    <time_frame>Month 1 through Month 24 Inclusive</time_frame>
    <description>Resistance to Blister Formation demonstrated by response to negative pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Neutrophil Engraftment</measure>
    <time_frame>Day 42 Post Transplant</time_frame>
    <description>Number of patients with an absolute neutrophil count &gt;5 x 10^8 cells/liter for 3 consecutive days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>Epidermolysis Bullosa (EB) Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Day -9 through Day -6: 1.1 mg/kg if &lt; 12 kg IV every 6 hours; 0.8 mg/kg if &gt; 12 kg.</description>
    <arm_group_label>Epidermolysis Bullosa (EB) Patients</arm_group_label>
    <other_name>Bulsulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Day -5 through Day -2: 50 mg/kg IV over 120 min.</description>
    <arm_group_label>Epidermolysis Bullosa (EB) Patients</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Day -5 through Day -3: 25 mg/m2 IV over 60 min.</description>
    <arm_group_label>Epidermolysis Bullosa (EB) Patients</arm_group_label>
    <other_name>Fludarabine</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hematopoietic bone marrow transplantation</intervention_name>
    <description>allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation</description>
    <arm_group_label>Epidermolysis Bullosa (EB) Patients</arm_group_label>
    <other_name>Bone marrow transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of epidermolysis bullosa (EB)

               -  Documented collagen type VII deficiency by:

                    -  Antigenic mapping (LH7.2 antibody)

                    -  Ultrastructure analysis of anchoring fibrils

                    -  DNA mutation analysis

          -  Performance status: &gt;50% Lansky; &gt;50% Karnofsky

          -  Adequate organ function

               -  Renal: glomerular filtration rate &gt; 60ml/min/1.73m2 patients aged â‰¤ 10 years

               -  Hepatic: bilirubin, aspartate aminotransferase/alanine aminotransferase
                  (AST/ALT), Alkaline phosphatase (ALP) &lt; 5 x upper limit of normal 4.2.3
                  Pulmonary: oxygen saturation &gt;92% 4.2.4 Cardiac: left ventricular ejection
                  fraction &gt; 45%.

          -  Healthy related hematopoietic stem cell donor available and meeting 1 of the following
             criteria:

               -  HLA-A, B, DRB1-identical sibling bone marrow and/or umbilical cord blood donor
                  (first priority)

               -  HLA-A, B, DRB1-matched or partially matched related donor (second priority)

               -  Donor may be a carrier but must be unaffected by EB

               -  8/8 HLA A, B, C, DRB1 allele level matched unrelated marrow donor (third
                  priority)

               -  7/8 HLA-A, B, C, DRB1 allele level matched unrelated marrow donor or 4/6 HLA-A, B
                  (antigen level), DRB1 (allele level) matched unrelated cord blood donor (fourth
                  priority)

        Exclusion criteria:

          -  Active infection at time of transplantation (including active infection with
             Aspergillus or other mold within 30 days)

          -  Squamous cell carcinoma of the skin

          -  History of human immunodeficiency virus (HIV) infection

          -  Prior transplantation with donor skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E. Wagner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2007</study_first_submitted>
  <study_first_submitted_qc>May 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <results_first_submitted>July 17, 2012</results_first_submitted>
  <results_first_submitted_qc>January 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2013</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epidermolysis bullosa</keyword>
  <keyword>dystrophic epidermolysis bullosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All subjects were registered with the BMT Biostatistical Support Group at the University of Minnesota.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Epidermolysis Bullosa (EB) Patients</title>
          <description>Epidermolysis bullosa patients enrolled for treatment with chemotherapy (Busulfan 0.8 or 1.1 mg/kg Days 6-9 before transplant; Fludarabine 25 mg/m^2 Days 3-5 before transplant; Cyclophosphamide 50 mg/kg Days 2-5 before transplant) and stem cell infusion (Day 0) followed by donor epidermal transplant .</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Epidermolysis Bullosa (EB) Patients</title>
          <description>Epidermolysis bullosa patients enrolled for treatment with chemotherapy (Busulfan 0.8 or 1.1 mg/kg Days 6-9 before transplant; Fludarabine 25 mg/m^2 Days 3-5 before transplant; Cyclophosphamide 50 mg/kg Days 2-5 before transplant) and stem cell infusion (Day 0) followed by donor epidermal transplant .</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With &gt;70% Donor Chimerism</title>
        <description>Number of patients with donor chimerism - percentage of donor cells in the patient via the peripheral blood or bone marrow.</description>
        <time_frame>Days 21, 100, 180, 365 and 730 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>Includes only patients that received transplant (one patient died prior to transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With &gt;70% Donor Chimerism</title>
          <description>Number of patients with donor chimerism - percentage of donor cells in the patient via the peripheral blood or bone marrow.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 730</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Transplant-Related Mortality</title>
        <description>Number of patients who died due to complications of the transplant (includes all deaths without previous relapse or progression).</description>
        <time_frame>Day 180 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>Includes only patients that received transplant (one patient died prior to transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Transplant-Related Mortality</title>
          <description>Number of patients who died due to complications of the transplant (includes all deaths without previous relapse or progression).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Platelet Engraftment</title>
        <description>Number of patients with a platelet count &gt;5 x 10^10 cells/liter for 3 consecutive measurements.</description>
        <time_frame>Day 180 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>Includes only patients that received transplant (one patient died prior to transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Platelet Engraftment</title>
          <description>Number of patients with a platelet count &gt;5 x 10^10 cells/liter for 3 consecutive measurements.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Acute Graft-Versus-Host Disease (GVHD)</title>
        <description>Number of patients with GVHD. Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.</description>
        <time_frame>Day 100 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>Includes only patients that received transplant (one patient died prior to transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Acute Graft-Versus-Host Disease (GVHD)</title>
          <description>Number of patients with GVHD. Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Chronic Graft-Versus-Host Disease (cGVHD)</title>
        <description>Number of patients with cGVHD; a severe long-term complication created by infusion of donor cells into a foreign host.</description>
        <time_frame>Day 365 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>Includes only patients that received transplant (one patient died prior to transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Chronic Graft-Versus-Host Disease (cGVHD)</title>
          <description>Number of patients with cGVHD; a severe long-term complication created by infusion of donor cells into a foreign host.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Survival is defined as the number of patients that were alive post transplant.</description>
        <time_frame>1 year and 2 years Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>Includes only patients that received transplant (one patient died prior to transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Survival is defined as the number of patients that were alive post transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Year Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Years Post Transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Donor Derived Cells in Skin</title>
        <description>Number of patients who had donor skin chimerism - donor cells in the patient's epidermis (a state in bone marrow transplantation in which bone marrow and host cells exist compatibly without signs of graft-versus-host rejection disease).</description>
        <time_frame>Day 90 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>Includes only patients that received transplant (one patient died prior to transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Donor Derived Cells in Skin</title>
          <description>Number of patients who had donor skin chimerism - donor cells in the patient's epidermis (a state in bone marrow transplantation in which bone marrow and host cells exist compatibly without signs of graft-versus-host rejection disease).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Resistance to Blister Formation</title>
        <description>Resistance to Blister Formation demonstrated by response to negative pressure.</description>
        <time_frame>Month 1 through Month 24 Inclusive</time_frame>
        <population>Added blister formation testing later in study; only 2 patients had pre-transplant test.</population>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>Includes only patients that received transplant (one patient died prior to transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Resistance to Blister Formation</title>
          <description>Resistance to Blister Formation demonstrated by response to negative pressure.</description>
          <population>Added blister formation testing later in study; only 2 patients had pre-transplant test.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Neutrophil Engraftment</title>
        <description>Number of patients with an absolute neutrophil count &gt;5 x 10^8 cells/liter for 3 consecutive days.</description>
        <time_frame>Day 42 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>Includes only patients that received transplant (one patient died prior to transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Neutrophil Engraftment</title>
          <description>Number of patients with an absolute neutrophil count &gt;5 x 10^8 cells/liter for 3 consecutive days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Detectable Collagen Type VII</title>
        <description>Number of patients with epidermolysis bullosa who had collagen type VII. Type VII collagen defects cause recessive dystrophic epidermolysis bullosa (RDEB), a blistering skin disorder often accompanied by epidermal cancers.</description>
        <time_frame>Day 100 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>Includes only patients that received transplant (one patient died prior to transplant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Detectable Collagen Type VII</title>
          <description>Number of patients with epidermolysis bullosa who had collagen type VII. Type VII collagen defects cause recessive dystrophic epidermolysis bullosa (RDEB), a blistering skin disorder often accompanied by epidermal cancers.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All subjects were monitored continuously and only serious unexpected and selected serious adverse experiences were collected during the first 100 days after cell infusion.</time_frame>
      <desc>Serious adverse events include: marrow engraftment failure, severe acute graft-versus-host (GVHD) (Grades III and IV), and death. Death was collected on 6 of 7 patients enrolled.</desc>
      <group_list>
        <group group_id="E1">
          <title>Epidermolysis Bullosa (EB) Patients</title>
          <description>Epidermolysis bullosa patients enrolled for treatment with chemotherapy (Busulfan 0.8 or 1.1 mg/kg Days 6-9 before transplant; Fludarabine 25 mg/m^2 Days 3-5 before transplant; Cyclophosphamide 50 mg/kg Days 2-5 before transplant) and stem cell infusion (Day 0) followed by donor epidermal transplant .</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <description>Candida sepsis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade IV skin toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John E. Wagner, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-626-2961</phone>
      <email>wagne002@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

